28 February 2024
28 February 2024
Novo Nordisk has partnered with US startup Neomorph to develop multiple molecular glue degraders for cardiometabolic disorders and rare diseases.
EXBLIFEP also received extended market exclusivity under the GAIN Act from the US regulator.
Whilst Minerva deals with clinical deficiencies, eyes turn to Karuna’s PDUFA date and other key Phase III readouts later this year.
The Phase II trial met its primary endpoint where 83% of patients saw an improvement in MASH compared to 18.2% on placebo.
A regulatory decision in the US for the application is anticipated in December 2024.
In an interview with Pharmaceutical Technology, the company’s chief scientific officer detailed the company’s upcoming 2024 plans.
Zambon will seek regulatory approval and subsequently market the therapy in Europe.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
